Project Grant R01NS133584

Award Date 6/1/24
Completion Date 5/31/27
Dollars Obligated $1.4M
Funding Federal Agency
Office of the Director
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
Ames, IA 50011, USA
Similar Awards
This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to examine the pathological white matter microstructural alterations and functional connectivity changes in the brain following exposure to the organophosphate compound diisopropylfluorophosphate (DFP). The $508,816 award will fund research to use high-resolution diffusion tensor imaging (DTI) and functional magnetic resonance imaging (fMRI) to analyze the...
This federal Project Grant award of $391,640.00, provided by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program, supports research to establish the freshwater planarian Dugesia japonica as a model for studying the developmental neurotoxicity of organophosphorus (OP) pesticides. The key objectives are to: 1) identify and characterize the key enzymes involved in OP bioactivation and detoxification in planarians, including...
This Project Grant award, provided by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) Federal Grant Program, aims to investigate the impact of exposure to organophosphate flame retardants (OPFRs) on metabolic and brain aging. The total funding amount is $409,508, with the award period running from September 16, 2024 to August 31, 2026. The key products and services to be delivered under this grant include: Defining the extent to...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program aims to develop an integrated platform that combines machine learning-based tools and in vitro neuronal assays to improve prediction of central nervous system toxicity associated with antisense oligonucleotides. The $862,420 award to Quiver Bioscience Inc. will fund research...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,830,581 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program to The Johns Hopkins University. The grant supports in-depth characterization of the mechanism of action of a new macrocycle molecule called RAPIREON, which selectively activates the nuclease activity of the IRE1 protein in the unfolded protein response (UPR) pathway....
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $208,328 to the University of Virginia to investigate small molecule activators of the 20S proteasome as a novel therapeutic strategy for treating neurodegenerative diseases. The overarching goals are to: 1) identify the mechanism by which N-acyl-fluspirilene compounds selectively enhance 20S proteasome activity, and 2) develop improved small molecule 20S proteasome activators. This research...
This $1,823,353 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the Seattle Institute For Biomedical And Clinical Research aims to elucidate the molecular mechanisms by which pathological tau protein causes neurodegeneration in Alzheimer's disease (AD) and related tauopathy disorders. The research project will leverage a C. elegans model of tauopathy to investigate the functional role of nuclear speckles, membraneless organelles involved in RNA...
This Project Grant award of $2,257,275.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a comprehensive, multi-omics investigation into the protein kinase signaling networks associated with the progression of Alzheimer's dementia (AD). The research team from the University of Toledo Health Science Campus will utilize postmortem brain samples and iPSC-derived neuronal, astrocyte, and microglia cell cultures to identify protein kinase networks and nodes that are...
The National Institute on Aging (NIA) has awarded a $3,474,488 Cooperative Agreement (CFDA 93.866 - Aging Research) to Emory University to develop a small-molecule antagonist of the EP2 receptor as a potential treatment for Alzheimer's disease (AD). The project aims to define the pharmacokinetic and pharmacodynamic relationships of the lead EP2 antagonist candidates on AD pathology markers in the brain and relevant biomarkers in the blood, cerebrospinal fluid, and brain tissue using mouse models...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate mechanisms of glial detection and facilitation of axonal regeneration. The total award amount is $218,068.00 over the project period from October 3, 2024 to December 31, 2026. The research aims to define the origins of a novel glial response involving the...

MECHANISMS OF NEURODEGENERATION IN A NERVE AGENT MODEL - PROJECT SUMMARY/ABSTRACT ORGANOPHOSPHATE (OP) NERVE AGENTS (OPNA) ARE INCREASINGLY USED TO ATTACK CIVILIANS WORLDWIDE. OPNA POISONING IS A GLOBAL HEALTH PROBLEM. THERE IS NO EFFECTIVE TREATMENT FOR OPNA SURVIVORS. THE LIFE-LONG HEALTH CONSEQUENCES OF OPNA SURVIVORS ARE BEGINNING TO EMERGE. HOWEVER, THE MECHANISMS OF OPNA-INDUCED LONG-TERM BRAIN INJURY ARE LARGELY UNKNOWN. ACUTE EXPOSURE TO OPNA INDUCES SEIZURES (NEURAL EXCITABILITY) AND STATUS EPILEPTICUS (SE). IN THE LONG TERM, SE-INDUCED BRAIN CHANGES ALTER THE SIGNALING MOLECULES IN NEURONS AND GLIA. WE HYPOTHESIZE THAT OPNA-INDUCED SE PROMOTES KEY MOLECULAR INTERACTIONS AND EXACERBATES NEURODEGENERATION, REACTIVE GLIOSIS, AND THE DEVELOPMENT OF EPILEPSY. IN RECENT YEARS, NOVEL PATHWAYS OF NEUROINFLAMMATION AND NEURODEGENERATION ARE EMERGING AS MECHANISTIC TARGETS FOR THERAPEUTIC DEVELOPMENT. OUR CURRENT FINDINGS AND OTHERS SUGGEST THAT A NON-RECEPTOR SRC FAMILY TYROSINE KINASE FYN AND A SERINE/THREONINE CYCLIN-DEPENDENT KINASE 5 (CDK5) ARE THE CRITICAL KINASES ACTIVATED IN BOTH NEURONS AND GLIA IN RESPONSE TO STATUS EPILEPTICS (SE) THAT PROMOTE NEUROINFLAMMATION, HYPEREXCITABILITY, AND NEURODEGENERATION. THE ACTIVATED FYN AND CDK5 CAN TRIGGER A SELF-PERPETUATING PATHWAY IN THE GLIA AND INTERACT WITH PHOSPHORYLATED TAU, NR2B, AND PSD95 IN NEURONS TO PROMOTE AND MAINTAIN THE DISEASE STATE. THEREFORE, OUR OVERARCHING HYPOTHESIS IS THAT THE SEIZURES INDUCED BY ACUTE EXPOSURE TO OPNA FACILITATE FYN-TAU INTERACTIONS IN NEURONS AND CDK5 AND FYN ACTIVATION IN BOTH GLIA AND NEURONS. THESE, IN TURN, ACTIVATE NR2B-PSD95 INTERACTIONS TO CAUSE NEURONAL HYPEREXCITABILITY (EPILEPTIFORM SPIKING AND SPONTANEOUS SEIZURES), REACTIVE GLIOSIS AND THE PRODUCTION OF PROINFLAMMATORY CYTOKINES (NEUROINFLAMMATION), NITROOXIDATIVE STRESS AND NEURODEGENERATION ("DISEASE PROMOTERS"), AND PROMOTE BRAIN PATHOGENESIS IN THE LONG TERM. WE WILL TEST THE HYPOTHESIS IN A WELL-CHARACTERIZED OPNA (DIISOPROPYLFLUOROPHOSPHATE (DFP)) RAT MODEL. IN SPECIFIC AIM 1 (SA1), AFTER ACUTE EXPOSURE TO DFP, WE WILL CHARACTERIZE THE CHANGES IN FYN, TAU, AND CDK5 AND THEIR INTERACTIONS AT VARIOUS TIME POINTS IN KEY BRAIN REGIONS. WE WILL FRACTIONATE BRAIN LYSATES TO ISOLATE SYNAPTOSOMAL MEMBRANES, CYTOSOL, AND NUCLEAR FRACTIONS AND CONDUCT CO-IMMUNOPRECIPITATION (CO-IP)/WB. WE WILL USE BRAIN SECTIONS FOR PROXIMITY LIGATION ASSAY (PLA) TO DETERMINE INTERACTING COMPLEXES AND IMMUNOHISTOCHEMISTRY FOR CELL-SPECIFIC LOCALIZATION OF SIGNALING MOLECULES, GLIOSIS, AND NEURODEGENERATION. IN SA2, WE WILL VALIDATE THESE INTERACTIONS USING FYN-TAU INTERACTIONS BLOCKING PEPTIDE AND A CDK5 INHIBITOR. WE WILL INVESTIGATE THE INTERACTIONS OF FYN AND CDK5 WITH NR2B AND PSD95 AND THEIR IMPACT ON HYPEREXCITABILITY, NEURODEGENERATION, AND PROTECTION BY PATHWAY INHIBITORS AND BLOCKING PEPTIDES. WE WILL INVESTIGATE PERIPHERAL BIOMARKERS OF NEURODEGENERATION IN THE SERUM AND CSF. THIS PROPOSAL IS IN RESPONSE TO THE CCRP INITIATIVE FOA (PAR-23-027), "WHICH IS EXPECTED TO GENERATE DATA THAT ELUCIDATE THE MECHANISMS OF OPNA-INDUCED BRAIN TOXICITY AND POTENTIAL NEW TARGETS FOR THERAPEUTIC DEVELOPMENT."

Posted 5/24/24, 12:00 AM